AFT Pharmaceuticals (AFT): Solid 2Q27 Update
AFT indicated it remains on track to reach NZ$300m in revenue in FY27, in line with our NZ$303m estimate Reiterated operating profit (EBIT) of...
88 Views
Primer: AFT Pharmaceuticals (AFT NZ) - Aug 2026
AFT Pharmaceuticals is poised for significant growth, driven by the global expansion of its flagship Maxigesic pain relief franchise and a...
99 Views
Primer: Aft Pharmaceuticals (AFP AU) - Aug 2026
Aft Pharmaceuticals is executing a dual-pronged growth strategy: maximizing commercial sales in its established Australasian markets while...
93 Views
AFT Pharmaceuticals Pipeline Prescribes Upside
AFT Pharmaceuticals (AFT) hosted a forward-looking investor day highlighting its attractive R&D pipeline. In the meantime, AFT’s operating...
117 Views
AFT Pharmaceuticals FY26 Result—Just What The Doctor Ordered
AFT Pharmaceuticals (AFT) reported a strong FY26 result, broadly in line with our expectations. First-time FY27 guidance was also in line with...
91 Views